The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Systematic review and meta-analysis of incremental cost-effectiveness ratio (ICER) for new cancer drugs.
 
Fernanda Alves Oliveira
No Relationships to Disclose
 
Eduardo Alves Oliveira
No Relationships to Disclose
 
Gilberto Lopes
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; E.R. Squibb Sons, LLC; Janssen; Pfizer
 
Joao Paulo SN Lima
Stock and Other Ownership Interests - Amgen; Bluebird Bio; Myriad Genetics; United Health Group
Honoraria - BMS Brazil; Libbs; MSD; Novartis
Consulting or Advisory Role - Roche
Speakers' Bureau - AstraZeneca
Research Funding - AstraZeneca (Inst); BMS Brazil (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Libbs (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - MSD; Novartis